There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > HGF R


HGF R Molecule Information

Name:Hepatocyte growth factor receptor
Target Synonym:MET;Proto-oncogene c-Met;Tyrosine-protein kinase Met;Scatter factor receptor;Hepatocyte growth factor receptor;SF receptor;HGF receptor;HGF/SF receptor
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:68
Lastest Research Phase:Approved

HGF R Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
Cat. No. Species Product Description Structure Purity Feature
MET-H82E1 Human Biotinylated Human HGF R / c-MET Protein, Avitag™,His Tag
MET-H5256 Human Human HGF R / c-MET Protein, Fc Tag
MET-H5227 Human Human HGF R / c-MET Protein, His Tag

HGF R Part of Bioactivity data

Human HGF R, His TagHuman HGF R, His Tag (Cat. No. MET-H5227) ELISA bioactivity

Immobilized Human HGF/Hepatocyte Growth Factor at 5 μg/mL (100 μL/well) can bind Human HGF R, His Tag (Cat. No. MET-H5227) with a linear range of 5-78 ng/mL (Routinely tested).

Biotinylated Human HGF R, Avitag,His TagBiotinylated Human HGF R, Avitag,His Tag (Cat. No. MET-H82E1) ELISA bioactivity

Immobilized Human HGF protein at 10 μg/mL (100 μL/well) can bind Biotinylated Human HGF R, Avitag,His Tag (Cat. No. MET-H82E1) with a linear range of 0.009-0.156 μg/mL (QC tested).

HGF R Molecule Synonym Name


HGF R Molecule Background

Hepatocyte growth factor receptor (HGFR) is also known as mesenchymal-epithelial transition factor (MET), c-Met, and is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGFR protein possesses tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. HGFR is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, HGFR induces several biological responses that collectively give rise to a program known as invasive growth. Abnormal HGFR activation in cancer correlates with poor prognosis, where aberrantly active HGFR triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). HGFR is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express HGFR, However, cancer stem cells are thought to hijack the ability of normal stem cells to express HGFR, and thus become the cause of cancer persistence and spread to other sites in the body. Various mutations in the HGFR gene are associated with papillary renal carcinoma. HGFR mediates a complex program known as invasive growth. Activation of HGFR triggers mitogenesis, and morphogenesis.

HGF R References

HGF R Related Molecule


HGF R Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Capmatinib INC-280; INCB-028060; INCB-28060; NVP-INC280-NX; C2A374O70X,INC280,INCB028060,INCB28060 Approved Novartis, Incyte TABRECTA fda NOVARTIS PHARM 2020-05-06 Non small cell lung cancer (NSCLC) Details
Tepotinib hydrochloride hydrate EMD-1214063; MSC-2156119; MSC-2156119J,EMD1214063,MSC2156119,MSC2156119J Approved Merck Serono Tepotinib 日本 Advanced non small cell lung cancer, Metastatic non-small cell lung cancer 默克雪兰诺 2020-03-25 00:00:00.0 Non small cell lung cancer (NSCLC), Metastatic non-small cell lung cancer, Advanced non small cell lung cancer Details
Crizotinib PF-02341066; PF-2341066; PF-002341066; PF-1066 Approved Pfizer XALKORI fda Non small cell lung cancer (NSCLC) PF PRISM CV 2011-08-26 Non small cell lung cancer (NSCLC), ROS1-positive non-small cell lung cancer (NSCLC) Details
Cabozantinib S-malate XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351 Approved Exelixis, Ipsen, Takeda COMETRIQ fda Medullary thyroid cancer (MTC) EXELIXIS 2012-11-29 Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC) Details

HGF R Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Merestinib LY-2801653; 5OGS5K699E,LY2801653 Phase Ⅱ Lilly Solid tumours Details
SAR-125844 SAR-125844,SAR125844 Phase Ⅱ Sanofi Non small cell lung cancer (NSCLC) Details
JNJ-38877605 JNJ-38877605,JNJ38877605 Phase Ⅰ Johnson & Johnson Solid tumours Details
Telisotuzumab vedotin ABBV-399; ABT-399 Phase Ⅱ Abbvie Non small cell lung cancer (NSCLC) Details
LDC-1267 LDC-1267 Preclinical Max Planck Innovation, Lead Discovery Center Cancer Details
Bozitinib CBI-3103; CBT-101;PLB-1001;APL-101 Phase Ⅱ Heng Kang, CBT, Beijing Pearl Biotechnology, Crown Bioscience Glioma, Non small cell lung cancer (NSCLC), Renal cell carcinoma, Solid tumours, Hepatocellular carcinoma (HCC) Details
LMV-12(HE003) LMV-12(HE003) Phase Ⅰ Helioeast Solid tumours Details
Golvatinib tartrate ER-396901-08; E-7050,ER39690108,E7050 Phase Ⅱ Eisai, QuintilesIMS Solid tumours, Hepatocellular carcinoma (HCC), Head and neck cancer Details
Sitravatinib MG-516; MG-91516; MGCD-516 Phase Ⅲ Mirati Therapeutics, BeiGene Non small cell lung cancer (NSCLC) Details
CBT-101 CBT-101 Phase Ⅰ CBT, Beijing Pearl Biotechnology Solid tumours Details
Amuvatinib MP-470; HPK-56,MP470,HPK56 Phase Ⅱ Astex Pharmaceuticals Small cell lung cancer (SCLC) Details
TAS-115 TAS-115,TAS115 Phase Ⅰ Otsuka, Taiho Pharma Solid tumours Details
SHR-A1403 SHR-A1403,SHRA1403 Phase Ⅰ Jiangsu Hengrui Medicine Solid tumours Details
SAIT-301 SAIT-301 Phase Ⅰ Samsung Medical Center Solid tumours Details
HQP8361 APG-8361; HQP-8361; MK-8033,HQP8361 Phase Ⅰ Merck Sharp & Dohme, Guangzhou Shun Jian Biomedical Technology, Guangzhou Baiyunshan Mingxing Pharmaceutical Solid tumours Details
MK-2461 MK-2461 Phase Ⅱ Merck Sharp & Dohme Solid tumours Details
Recombinant plasmid-hepatocyte growth factor Pudk-HGF Phase Ⅲ Academy of Military Medical Sciences, Wuhan Guanggu Humanwell Healthcare Peripheral arterial disease (PAD) Details
ABT-700 ABT-700; h224G11; Mab224G11; Mabh224G11 Phase Ⅰ Pierre Fabre, Abbvie Solid tumours Details
PF-04217903 PF-4217903; PF-04217903; PF-4217903-A ,PF04217903,PF4217903 Phase Ⅰ Pfizer Solid tumours Details
SGX-523 SGX-523,SGX523 Phase Ⅰ Lilly Solid tumours Details
Golvatinib/Lenvatinib Phase Ⅱ Eisai Glioblastoma, Angiomas, Melanoma Details
Kanitinib CX-1003,CX1003 Phase Ⅰ Beijing Konruns Pharmaceutical, Guangzhou ESA Biotech Metastatic prostate carcinoma, Gastroesophageal junction adenocarcinoma Details
ABN-401 ABN-401; KDDF-201603-08 Phase Ⅱ Abion Inc Solid tumours Details
GST-HG161 GST-HG161 Phase Ⅰ WuXi AppTec, Fujian Cosunter Pharmaceutical Hepatocellular carcinoma (HCC) Details
EMD-1204831 EMD-1204831 Phase Ⅰ Merck Serono Solid tumours Details
Altiratinib DCC-22701; DCC-2701; DP-5164; T-678746713 Phase Ⅰ Deciphera Solid tumours Details
Ningetinib Tosylate CT-053-PTSA; CT-053 Phase Ⅱ HEC Pharm Non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC), Renal carcinoma Details
Emibetuzumab LA-480; LY-2875358 Phase Ⅱ Lilly Gastric cancer, Non small cell lung cancer (NSCLC) Details
QBH-196 QBH-196 Phase Ⅰ Shenyang Pharmaceutical University Gastric cancer Details
CM-118 CM-118,CM118 Phase Ⅰ Xcovery, Shanghai Zaixin Pharmaceutical Non small cell lung cancer (NSCLC), Malignancies Details
Boxitinib Hydrochloride Phase Ⅰ HEC Pharm Glioma, Gastric cancer, Breast cancer, Lung cancer, Renal carcinoma Details
HS-10241 HS-10241,HS10241 Phase Ⅰ Hansoh Pharma Gastric cancer, Solid tumours, Lung cancer, Liver cancer Details
Hepapoietin (Atlas Pharmaceuticals) APS-1010 Phase Ⅱ Daiichi Sankyo, Atlas Pharma Kidney disorders, Hepatic disorders Details
Volitinib AZD-6094; HMP-504; HMPL-504; HM-5016504 NDA Filing Hutchison Medipharma, AstraZeneca Non small cell lung cancer (NSCLC) Details
AL-2846 AL-2846,AL2846 Phase Ⅱ Chiatai Tianqing (CTTQ), Nanjing Advenchen Laboratories Glioma, Non small cell lung cancer (NSCLC), Gastric cancer, Prostate cancer, Medullary thyroid cancer (MTC), Liver cancer Details
AMG-208 AMG-208,AMG208 Phase Ⅱ Amgen Prostate cancer, Solid tumours Details
Tivantinib ARQ-197 ,ARQ197,ARQ 197 Phase Ⅲ ArQule, Daiichi Sankyo, Kyowa Hakko Kirin Non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC) Details
TPX-0022 TPX-0022 Phase Ⅰ Turning Point Therapeutics Solid tumours Details
NP-01 (Shijiazhuang No.4 Pharmaceutical/Nanjing Nadingfei Medical Technology) NP-01 IND Filing Shijiazhuang No.4 Pharmaceutical, Nanjing Nadingfei Medical Technology Gastric cancer, Prostate cancer, Lung cancer, Liver cancer Details
ASLAN-002 ASLAN-002; BMS-777607; BMS-797669 Phase Ⅱ Bristol-Myers Squibb, Aslan Gastric cancer, Breast cancer Details
MCLA-129 MCLA-129 Preclinical Merus, Betta Solid tumours Details
Anti-cMet SIMPLE Antibody ARGX-111 Phase Ⅰ arGEN-X Solid tumours Details
Refanalin ANG-3777; BB-3; SNV-003 Phase Ⅲ Angion Biomedica, sinovant Delayed graft function Details
EM1-mAb DuoBody (Genmab) Ab-957 Preclinical Genmab, Janssen Autoimmune diseases Details
Foretinib EXEL-2880; XL-880; GSK-1363089; GSK-089; GSK-1363089G Phase Ⅱ Exelixis Non small cell lung cancer (NSCLC), Breast cancer Details
LY-3164530 LY-3164530 Phase Ⅰ Lilly Solid tumours Details
Alirinetide GM-6; GM-600; GM-602; GM-603; GM-604; GM-605; GM-606; GM-607; GM-608; GM-609 Phase Ⅱ Genervon Amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Ischemic stroke Details
DBPR-114 Phase Ⅰ National Health Research Institutes Cancer Details
BMS-794833 BMS-794833,BMS794833 Preclinical Bristol-Myers Squibb Solid tumours Details
EMB-01 EMB-01 Phase Ⅱ EpimAb Biotherapeutics Solid tumours Details
Metatinib Trometamol BMS-817378; SIM-817378 Phase Ⅰ Bristol-Myers Squibb, Simcere Non small cell lung cancer (NSCLC), Gastric cancer, Metastatic colorectal cancer (CRC), Liver cancer Details
[18F]-AH113804 [18F]-AH113804 Preclinical GE Healthcare Diagnostic agents Details
EMD-94283 EMD-94283 Phase Ⅰ Merck Serono Cancer Details
Amivantamab JNJ-61186372; JNJ-372 Phase Ⅲ Genmab, Janssen Non small cell lung cancer (NSCLC) Details
Onartuzumab OA-5D5; PRO-143966; RG-3638; RO-5490258,OA5D5,PRO143966,RG3638,RO5490258 Phase Ⅲ Genentech, Chugai Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Solid tumours, Colorectal cancer, Hepatocellular carcinoma (HCC), Glioblastoma Details
Glumetinib HH-SCC244; SCC244 Phase Ⅱ Shanghai Institute of Materia Medica, Shanghai Green Valley Pharmaceutical, Haihe Biopharma Non small cell lung cancer (NSCLC) Details
SPH3348 SPH-3348 Phase Ⅰ Shanghai Pharma Gastric cancer, Lung cancer, Liver cancer Details
XL-092 XL-092 Phase Ⅰ Exelixis Cancer Details
Sym-015 Sym-015 Phase Ⅱ Symphogen Lung cancer Details
RXDX-106 RXDX-106 Phase Ⅰ Teva, Daiichi Sankyo, Roche Solid tumours Details
AMG-337 AMG-337,AMG337 Phase Ⅱ Amgen, NantPharma, Astellas Gastric cancer, Esophageal adenocarcinoma, Solid tumours Details
Glesatinib MGCD-265; MG-90265; MG-90265H9; MG-90265X; MG-90265gly; 7Q29OXD98N,MGCD265 Phase Ⅱ Mirati Therapeutics Non small cell lung cancer (NSCLC), Solid tumours Details
Recombinant human hepatocyte growth factor (Kyoto University) Phase Ⅱ Kyoto University Liver failure Details
JNJ-38877618 JNJ-38877618; OMO-1 Phase Ⅱ Johnson & Johnson Solid tumours Details
MK-8033 MK-8033,MK8033 Phase Ⅰ Merck Sharp & Dohme Solid tumours Details
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) Phase Ⅰ The Second Hospital of Nanjing Medical University Primary hepatocellular carcinoma Details
BPI-9016 BPI-9016M; BPI-9016 Phase Ⅰ Betta Non small cell lung cancer (NSCLC) Details
S-49076 S-49076,S49076 Phase Ⅱ Servier Non small cell lung cancer (NSCLC), Glioblastoma Details

This web search service is supported by Google Inc.